Literature DB >> 26792164

The diagnostic accuracy of integrated positron emission tomography/computed tomography in the evaluation of pulmonary mass lesions in a tuberculosis-endemic area.

R du Toit1, J A Shaw, E M Irusen, F von Groote-Bidlingmaier, J M Warwick, C F N Koegelenberg.   

Abstract

BACKGROUND: Integrated positron emission tomography/computed tomography (PET-CT) is a well-validated modality for assessing pulmonary mass lesions and specifically for estimating risk of malignancy. Tuberculosis (TB) is known to cause false-positive PET-CT findings.
OBJECTIVE: To investigate the utility of PET-CT in the evaluation of pulmonary mass lesions and nodules in a high TB prevalence setting.
METHODS: All patients referred for the evaluation of a solitary pulmonary nodule or mass and who underwent PET-CT scanning over a 3-year period were included. The PET-CT findings, including maximum standardised uptake value (SUVmax), were compared with the gold standard (tissue or microbiological diagnosis). The sensitivity, specificity, positive and negative predictive values and diagnostic accuracy for malignant disease were calculated according to the SUVmax cut-off of 2.5 and a proposed cut-off obtained from a receiver operating characteristic (ROC) curve.
RESULTS: Forty-nine patients (mean (standard deviation) age 60.1 (10.2) years; 29 males) were included, of whom 30 had malignancy. Using an SUVmax cut-off of 2.5, PET-CT had a sensitivity, specificity, positive and negative predictive value and diagnostic accuracy for malignancy of 93.3%, 36.8%, 70.0%, 77.8% and 71.4%, respectively. After a ROC curve analysis, a suggested SUVmax cut-off of 5.0 improved the specificity to 78.9% and the diagnostic accuracy to 86.7%, with a small reduction in sensitivity to 90.0%.
CONCLUSIONS: The diagnostic accuracy of PET-CT in the evaluation of pulmonary mass lesions using the conventional SUVmax cut-off of 2.5 was reduced in a TB-endemic area. An SUVmax cut-off of 5.0 has a higher specificity and diagnostic accuracy for malignancy, with a comparable sensitivity.

Entities:  

Year:  2015        PMID: 26792164     DOI: 10.7196/SAMJ.2015.v105i12.10300

Source DB:  PubMed          Journal:  S Afr Med J


  5 in total

Review 1.  Recommendations for lung cancer screening in Southern Africa.

Authors:  Coenraad F N Koegelenberg; Shane Dorfman; Ivan Schewitz; Guy A Richards; Shaun Maasdorp; Clifford Smith; Keertan Dheda
Journal:  J Thorac Dis       Date:  2019-09       Impact factor: 2.895

2.  Lung Cancer Screening Considerations During Respiratory Infection Outbreaks, Epidemics or Pandemics: An International Association for the Study of Lung Cancer Early Detection and Screening Committee Report.

Authors:  Rudolf M Huber; Milena Cavic; Anna Kerpel-Fronius; Lucia Viola; John Field; Long Jiang; Ella A Kazerooni; Coenraad F N Koegelenberg; Anant Mohan; Ricardo Sales Dos Santos; Luigi Ventura; Murry Wynes; Dawei Yang; Javier Zulueta; Choon-Taek Lee; Martin C Tammemägi; Claudia I Henschke; Stephen Lam
Journal:  J Thorac Oncol       Date:  2021-12-03       Impact factor: 15.609

3.  Staging and operability of primary lung cancer in Western Cape Province, South Africa.

Authors:  M A Parker; M S Moolla; G E Paris; C F N Koegelenberg
Journal:  Afr J Thorac Crit Care Med       Date:  2022-05-05

4.  Asymptomatic pulmonary tuberculosis mimicking lung cancer on imaging: A retrospective study.

Authors:  Shan Lang; Junping Sun; Xuning Wang; Yongjiu Xiao; Juan Wang; Mingyue Zhang; Ting Ao; Jianxin Wang
Journal:  Exp Ther Med       Date:  2017-07-09       Impact factor: 2.447

5.  Evaluation of the diagnostic efficacy of 18 F-Fluorine-2-Deoxy-D-Glucose PET/CT for lung cancer and pulmonary tuberculosis in a Tuberculosis-endemic Country.

Authors:  Alexandre Niyonkuru; Xiaomin Chen; Khamis Hassan Bakari; Dilani Neranjana Wimalarathne; Altine Bouhari; Maher Mohamad Rajab Arnous; Xiaoli Lan
Journal:  Cancer Med       Date:  2019-12-13       Impact factor: 4.452

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.